Skip to content

Omeros OMER Financing Cash Flow

Financing Cash Flow at other companies

Cullinan Therapeutics, Inc. logo
Cullinan Therapeutics, Inc.CGEM
$380K
Nektar Therapeutics logo
Nektar TherapeuticsNKTR
$529.55M+7,564,886%
Immunome logo
ImmunomeIMNM
-$135K-100%
Vor Biopharma logo
Vor BiopharmaVOR
$74.87M+12,455%
Annexon logo
AnnexonANNX
$32.9M+55,656%
Arcus Biosciences logo
Arcus BiosciencesRCUS
$3M-97.9%

Other financials

Income statement

See full
Revenue$9.9M
Gross profit$29.7M
Operating income-$40.9M-9.2%
Net income$56.1M+268%
EPS (diluted)-$0.59-20.4%

Balance sheet

See full
Cash & equivalents$1.9M-55.3%
Total debt$13.5M-30.3%
Total equity-$63.3M+70.3%
Total assets$286.2M+21.7%

Cash flow

See full
Operating cash flow-$14.5M+59.5%
CapEx--100%
Free cash flow-$14.5M+59.6%

Valuation

See full
Market cap$765.73M+307%
P/S8.5×

Profitability

See full
Gross margin98.9%
Operating margin-181.8%
Net margin-136.6%
FCF margin-121.6%

Returns & leverage

See full
Return on equity86.6%
Debt / equity0.3×-1.1×
Current ratio+1.9×

Where this comes from

Reported directly by Omeros in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Omeros’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Omeros's financing cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Omeros's financing cash flow?
Omeros (OMER) reported financing cash flow of -$21.98M in Q1 2026.
How has Omeros's financing cash flow changed year-over-year?
Omeros's financing cash flow decreased by 1095.3% year-over-year, from -$1.84M to -$21.98M.
What does financing cash flow mean?
Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.